1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Leukemia - Pipeline Review, 2015

Leukemia - Pipeline Review, 2015

  • October 2015
  • -
  • Global Data
  • -
  • 93 pages

Leukemia - Pipeline Review, 2015

Summary

GlobalData's Medical Devices sector report, “Leukemia - Pipeline Review, 2015" provides an overview of Leukemia diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Leukemia diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Leukemia diagnostic tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Leukemia diagnostic tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Leukemia diagnostic tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date

Table Of Contents

Leukemia - Pipeline Review, 2015
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 4
1.2 List of Figures 7
2 Introduction 8
2.1 Leukemia Overview 8
3 Products under Development 9
3.1 Leukemia - Pipeline Products by Stage of Development 9
3.2 Leukemia - Pipeline Products by Territory 10
3.3 Leukemia - Pipeline Products by Regulatory Path 11
3.4 Leukemia - Pipeline Products by Estimated Approval Date 12
4 Leukemia - Pipeline Products under Development by Companies 13
4.1 Leukemia Companies - Pipeline Products by Stage of Development 13
4.2 Leukemia - Pipeline Products by Stage of Development 15
5 Leukemia Companies and Product Overview 18
5.1 Abbott Diagnostics Company Overview 18
5.1.1 Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 18
5.2 Acobiom Company Overview 22
5.2.1 Acobiom Pipeline Products and Ongoing Clinical Trials Overview 22
5.3 Adaptive Biotechnologies Corporation Company Overview 23
5.3.1 Adaptive Biotechnologies Corporation Pipeline Products and Ongoing Clinical Trials Overview 23
5.4 BioSense Technologies, Inc. Company Overview 24
5.4.1 BioSense Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 24
5.5 Cancer Genetics, Inc. Company Overview 25
5.5.1 Cancer Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
5.6 Cepheid Company Overview 27
5.6.1 Cepheid Pipeline Products and Ongoing Clinical Trials Overview 27
5.7 Di.V.A.L Toscana srl Company Overview 29
5.7.1 Di.V.A.L Toscana srl Pipeline Products and Ongoing Clinical Trials Overview 29
5.8 Diagnovus, LLC Company Overview 30
5.8.1 Diagnovus, LLC Pipeline Products and Ongoing Clinical Trials Overview 30
5.9 DiaSorin S.p.A Company Overview 31
5.9.1 DiaSorin S.p.A Pipeline Products and Ongoing Clinical Trials Overview 31
5.10 Eutropics Pharmaceuticals, Inc. Company Overview 37
5.10.1 Eutropics Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 37
5.11 Gendiag Company Overview 41
5.11.1 Gendiag Pipeline Products and Ongoing Clinical Trials Overview 41
5.12 Health Discovery Corporation Company Overview 42
5.12.1 Health Discovery Corporation Pipeline Products and Ongoing Clinical Trials Overview 42
5.13 InVivoScribe Technologies, Inc. Company Overview 44
5.13.1 InVivoScribe Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 44
5.14 IV Diagnostics, Inc. Company Overview 46
5.14.1 IV Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 46
5.15 Jaden BioScience Inc. Company Overview 47
5.15.1 Jaden BioScience Inc. Pipeline Products and Ongoing Clinical Trials Overview 47
5.16 MolecularMD, Corp. Company Overview 48
5.16.1 MolecularMD, Corp. Pipeline Products and Ongoing Clinical Trials Overview 48
5.17 Monoquant Pty. Ltd. Company Overview 49
5.17.1 Monoquant Pty. Ltd. Pipeline Products and Ongoing Clinical Trials Overview 49
5.18 Nodality, Inc. Company Overview 50
5.18.1 Nodality, Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
5.19 NuCana BioMed Limited Company Overview 51
5.19.1 NuCana BioMed Limited Pipeline Products and Ongoing Clinical Trials Overview 51
5.20 Nuclea Biotechnologies Inc. Company Overview 59
5.20.1 Nuclea Biotechnologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 59
5.21 OncoVista Innovative Therapies, Inc. Company Overview 62
5.21.1 OncoVista Innovative Therapies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 62
5.22 Qiagen N.V. Company Overview 64
5.22.1 Qiagen N.V. Pipeline Products and Ongoing Clinical Trials Overview 64
5.23 Siemens Healthcare Diagnostics Inc. Company Overview 66
5.23.1 Siemens Healthcare Diagnostics Inc. Pipeline Products and Ongoing Clinical Trials Overview 66
5.24 Skyline Diagnostics BV Company Overview 68
5.24.1 Skyline Diagnostics BV Pipeline Products and Ongoing Clinical Trials Overview 68
5.25 St. Jude Children's Research Hospital, Inc. Company Overview 70
5.25.1 St. Jude Children's Research Hospital, Inc. Pipeline Products and Ongoing Clinical Trials Overview 70
5.26 The Feinstein Institute for Medical Research Company Overview 73
5.26.1 The Feinstein Institute for Medical Research Pipeline Products and Ongoing Clinical Trials Overview 73
5.27 University of Barcelona Company Overview 75
5.27.1 University of Barcelona Pipeline Products and Ongoing Clinical Trials Overview 75
5.28 University of California, San Diego Company Overview 76
5.28.1 University of California, San Diego Pipeline Products and Ongoing Clinical Trials Overview 76
5.29 University of Missouri Company Overview 78
5.29.1 University of Missouri Pipeline Products and Ongoing Clinical Trials Overview 78
5.30 Vela Diagnostics Company Overview 79
5.30.1 Vela Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 79
5.31 Vivia Biotech, S.L. Company Overview 80
5.31.1 Vivia Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 80
5.32 Wake Forest Baptist Medical Center Company Overview 83
5.32.1 Wake Forest Baptist Medical Center Pipeline Products and Ongoing Clinical Trials Overview 83
5.33 Xiamen Zeesan Biotech Co.,Ltd Company Overview 85
5.33.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 85
6 Leukemia- Recent Developments 87
7 Appendix 90
7.1 Methodology 90
7.2 About GlobalData 92
7.3 Contact Us 93
7.4 Disclaimer 93

1.1 List of Tables
Table 1: Leukemia - Pipeline Products by Stage of Development 9
Table 2: Leukemia - Pipeline Products by Territory 10
Table 3: Leukemia - Pipeline Products by Regulatory Path 11
Table 4: Leukemia - Pipeline Products by Estimated Approval Date 12
Table 5: Leukemia Companies - Pipeline Products by Stage of Development 13
Table 6: Leukemia - Pipeline Products by Stage of Development 15
Table 7: Abbott Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 18
Table 8: CRLF2 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status 18
Table 9: CRLF2 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description 19
Table 10: D13S319/CEP12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 19
Table 11: D13S319/CEP12 Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 19
Table 12: IKZF1 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Status 20
Table 13: IKZF1 Companion Diagnostic Assay - Acute Lymphocytic Leukemia - Product Description 20
Table 14: MCL1 Companion Diagnostic Assay - Leukemia - Product Status 20
Table 15: MCL1 Companion Diagnostic Assay - Leukemia - Product Description 21
Table 16: TP53/ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Status 21
Table 17: TP53/ATM Companion Diagnostic Assay - Chronic Lymphocytic Leukemia - Product Description 21
Table 18: Acobiom Pipeline Products and Ongoing Clinical Trials Overview 22
Table 19: Diagnostic Assay - Chronic Myelomonocytic Leukemia - Product Status 22
Table 20: Diagnostic Assay - Chronic Myelomonocytic Leukemia - Product Description 22
Table 21: Adaptive Biotechnologies Corporation Pipeline Products and Ongoing Clinical Trials Overview 23
Table 22: MRD Assay - B-cell Acute Lymphoblastic Leukemia - Product Status 23
Table 23: MRD Assay - B-cell Acute Lymphoblastic Leukemia - Product Description 23
Table 24: BioSense Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 24
Table 25: Diagnostic Assay - BCR-ABL (+) - Product Status 24
Table 26: Diagnostic Assay - BCR-ABL (+) - Product Description 24
Table 27: Cancer Genetics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 25
Table 28: LeukA - Leukemia - Product Status 26
Table 29: LeukA - Leukemia - Product Description 26
Table 30: Cepheid Pipeline Products and Ongoing Clinical Trials Overview 27
Table 31: XPERT CLL Monitoring Test - Product Status 28
Table 32: XPERT CLL Monitoring Test - Product Description 28
Table 33: Di.V.A.L Toscana srl Pipeline Products and Ongoing Clinical Trials Overview 29
Table 34: NanoMabKv - Leukemia - Product Status 29
Table 35: NanoMabKv - Leukemia - Product Description 29
Table 36: Diagnovus, LLC Pipeline Products and Ongoing Clinical Trials Overview 30
Table 37: Diagnostic Assay - Leukemia - Product Status 30
Table 38: Diagnostic Assay - Leukemia - Product Description 30
Table 39: DiaSorin S.p.A Pipeline Products and Ongoing Clinical Trials Overview 31
Table 40: AML-ETO 1 Assay - Product Status 32
Table 41: AML-ETO 1 Assay - Product Description 32
Table 42: C-Kit 816 Assay - Product Status 33
Table 43: C-Kit 816 Assay - Product Description 33
Table 44: C-Kit 822 Assay - Product Status 34
Table 45: C-Kit 822 Assay - Product Description 34
Table 46: LIAISON IAM - Acute Lymphoblastic Leukemia Test - Product Status 35
Table 47: LIAISON IAM - Acute Lymphoblastic Leukemia Test - Product Description 35
Table 48: LIAISON IAM - Acute Promyelocitic Leukemia - Product Status 36
Table 49: LIAISON IAM - Acute Promyelocitic Leukemia - Product Description 36
Table 50: Eutropics Pharmaceuticals, Inc. Pipeline Products and Ongoing Clinical Trials Overview 37
Table 51: Companion Diagnostic Assay - Alvocidib - Product Status 38
Table 52: Companion Diagnostic Assay - Alvocidib - Product Description 38
Table 53: Diagnostic Test - Acute Lymphoid Leukemia - Product Status 39
Table 54: Diagnostic Test - Acute Lymphoid Leukemia - Product Description 39
Table 55: EU-4030 Companion Diagnostic Assay - AML - Product Status 40
Table 56: EU-4030 Companion Diagnostic Assay - AML - Product Description 40
Table 57: Gendiag Pipeline Products and Ongoing Clinical Trials Overview 41
Table 58: Hemato inCode DNA Chip - Product Status 41
Table 59: Hemato inCode DNA Chip - Product Description 41
Table 60: Health Discovery Corporation Pipeline Products and Ongoing Clinical Trials Overview 42
Table 61: Diagnostic Test - Pre-Leukemia - Product Status 43
Table 62: Diagnostic Test - Pre-Leukemia - Product Description 43
Table 63: InVivoScribe Technologies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 44
Table 64: FLT3 Biomarker - Acute Myeloid Leukemia - Product Status 45
Table 65: FLT3 Biomarker - Acute Myeloid Leukemia - Product Description 45
Table 66: IV Diagnostics, Inc. Pipeline Products and Ongoing Clinical Trials Overview 46
Table 67: Diagnostic Test - Leukemia - Product Status 46
Table 68: Diagnostic Test - Leukemia - Product Description 46
Table 69: Jaden BioScience Inc. Pipeline Products and Ongoing Clinical Trials Overview 47
Table 70: Ultrasensitive Assay - B-Cell Chronic Lymphocytic Leukemia - Product Status 47
Table 71: Ultrasensitive Assay - B-Cell Chronic Lymphocytic Leukemia - Product Description 47
Table 72: MolecularMD, Corp. Pipeline Products and Ongoing Clinical Trials Overview 48
Table 73: Notch1 NGS Test - Chronic Lymphocytic Leukemia - Product Status 48
Table 74: Notch1 NGS Test - Chronic Lymphocytic Leukemia - Product Description 48
Table 75: Monoquant Pty. Ltd. Pipeline Products and Ongoing Clinical Trials Overview 49
Table 76: PCR-Based Diagnostic Test - Chronic Myeloid Leukemia - Product Status 49
Table 77: PCR-Based Diagnostic Test - Chronic Myeloid Leukemia - Product Description 49
Table 78: Nodality, Inc. Pipeline Products and Ongoing Clinical Trials Overview 50
Table 79: Acute Myeloid Leukemia Induction Response Test - Product Status 50
Table 80: Acute Myeloid Leukemia Induction Response Test - Product Description 50
Table 81: NuCana BioMed Limited Pipeline Products and Ongoing Clinical Trials Overview 51
Table 82: NUC-10000 Companion Diagnostic Test - Product Status 52
Table 83: NUC-10000 Companion Diagnostic Test - Product Description 52
Table 84: NUC-11000 Companion Diagnostic Test - Product Status 53
Table 85: NUC-11000 Companion Diagnostic Test - Product Description 53
Table 86: NUC-12000 Companion Diagnostic Test - Product Status 54
Table 87: NUC-12000 Companion Diagnostic Test - Product Description 54
Table 88: NUC-5435 Companion Diagnostic Test - Product Status 55
Table 89: NUC-5435 Companion Diagnostic Test - Product Description 55
Table 90: NUC-6285 Companion Diagnostic Test - Product Status 56
Table 91: NUC-6285 Companion Diagnostic Test - Product Description 56
Table 92: NUC-7000 Companion Diagnostic Test - Product Status 57
Table 93: NUC-7000 Companion Diagnostic Test - Product Description 57
Table 94: NUC-8000 Companion Diagnostic Test - Product Status 58
Table 95: NUC-8000 Companion Diagnostic Test - Product Description 58
Table 96: Nuclea Biotechnologies Inc. Pipeline Products and Ongoing Clinical Trials Overview 59
Table 97: CML Detection Test - Product Status 60
Table 98: CML Detection Test - Product Description 60
Table 99: MLL Detection Test - Product Status 61
Table 100: MLL Detection Test - Product Description 61
Table 101: OncoVista Innovative Therapies, Inc. Pipeline Products and Ongoing Clinical Trials Overview 62
Table 102: OVI-123(Cordycepin) Biomarker - Leukemia - Product Status 63
Table 103: OVI-123(Cordycepin) Biomarker - Leukemia - Product Description 63
Table 104: Qiagen N.V. Pipeline Products and Ongoing Clinical Trials Overview 64
Table 105: ABL Assay - Product Status 65
Table 106: ABL Assay - Product Description 65
Table 107: Siemens Healthcare Diagnostics Inc. Pipeline Products and Ongoing Clinical Trials Overview 66
Table 108: Companion Diagnostic Test - Inotuzumab Ozogamicin - Product Status 67
Table 109: Companion Diagnostic Test - Inotuzumab Ozogamicin - Product Description 67
Table 110: Skyline Diagnostics BV Pipeline Products and Ongoing Clinical Trials Overview 68
Table 111: ALL Profiler - Product Status 68
Table 112: ALL Profiler - Product Description 68
Table 113: AMLProfiler - Product Status 69
Table 114: AMLProfiler - Product Description 69
Table 115: St. Jude Children's Research Hospital, Inc. Pipeline Products and Ongoing Clinical Trials Overview 70
Table 116: Biomarker Based Assay - MRD ALL - Product Status 71
Table 117: Biomarker Based Assay - MRD ALL - Product Description 71
Table 118: Diagnostic Assay - MRD In Leukemia - Product Status 72
Table 119: Diagnostic Assay - MRD In Leukemia - Product Description 72
Table 120: The Feinstein Institute for Medical Research Pipeline Products and Ongoing Clinical Trials Overview 73
Table 121: Prognostic Test - Chronic Lymphocytic Leukemia - Product Status 74
Table 122: Prognostic Test - Chronic Lymphocytic Leukemia - Product Description 74
Table 123: University of Barcelona Pipeline Products and Ongoing Clinical Trials Overview 75
Table 124: Prognostic Assay - Chronic Lymphocytic Leukemia - Product Status 75
Table 125: Prognostic Assay - Chronic Lymphocytic Leukemia - Product Description 75
Table 126: University of California, San Diego Pipeline Products and Ongoing Clinical Trials Overview 76
Table 127: Biomarker Assay - Chronic Lymphocytic Leukemia - Product Status 76
Table 128: Biomarker Assay - Chronic Lymphocytic Leukemia - Product Description 76
Table 129: ROR1 Monoclonal Antibody Assay - Product Status 77
Table 130: ROR1 Monoclonal Antibody Assay - Product Description 77
Table 131: University of Missouri Pipeline Products and Ongoing Clinical Trials Overview 78
Table 132: Multiple Methylation Sensitive Enzyme Restriction PCR (MSR-PCR) Assay - Product Status 78
Table 133: Multiple Methylation Sensitive Enzyme Restriction PCR (MSR-PCR) Assay - Product Description 78
Table 134: Vela Diagnostics Pipeline Products and Ongoing Clinical Trials Overview 79
Table 135: Sentosa SQ Leukemia Panel - Product Status 79
Table 136: Sentosa SQ Leukemia Panel - Product Description 79
Table 137: Vivia Biotech, S.L. Pipeline Products and Ongoing Clinical Trials Overview 80
Table 138: Personalized Medicine Test - Acute Lymphocytic Leukemia - Product Status 81
Table 139: Personalized Medicine Test - Acute Lymphocytic Leukemia - Product Description 81
Table 140: Personalized Medicine Test - Chronic Lymphocytic Leukemia - Product Status 82
Table 141: Personalized Medicine Test - Chronic Lymphocytic Leukemia - Product Description 82
Table 142: Wake Forest Baptist Medical Center Pipeline Products and Ongoing Clinical Trials Overview 83
Table 143: Diagnostic Assay - Acute Erythroid Leukemia - Product Status 84
Table 144: Diagnostic Assay - Acute Erythroid Leukemia - Product Description 84
Table 145: Xiamen Zeesan Biotech Co.,Ltd Pipeline Products and Ongoing Clinical Trials Overview 85
Table 146: Theranostic Test - Leukemia Fusion - Product Status 85
Table 147: Theranostic Test - Leukemia Fusion - Product Description 85
Table 148: Theranostic Test - Leukemia Mutation - Product Status 86
Table 149: Theranostic Test - Leukemia Mutation - Product Description 86
Table 150: Glossary 91

1.2 List of Figures
Figure 1: Leukemia - Pipeline Products by Stage of Development 9
Figure 2: Leukemia - Pipeline Products by Territory 10
Figure 3: Leukemia - Pipeline Products by Regulatory Path 11
Figure 4: Leukemia - Pipeline Products by Estimated Approval Date 12

Companies Mentioned
Abbott Diagnostics
Acobiom
Adaptive Biotechnologies Corporation
BioSense Technologies, Inc.
Cancer Genetics, Inc.
Cepheid
Di.V.A.L Toscana srl
Diagnovus, LLC
DiaSorin S.p.A
Eutropics Pharmaceuticals, Inc.
Gendiag
Health Discovery Corporation
InVivoScribe

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1) - Pipeline Review, H2 2016

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase ...

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline ...

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2016

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cyclin Dependent Kinase 2 (p33 ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.